Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases

Jonas, Jost B.; Kreissig, Ingrid; Degenring, Robert F.

doi:10.1016/j.preteyeres.2005.01.004

Cited by 155 publications

(107 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients received an intravitreal high-dose injection of triamcinolone acetonide of about 20 mg as single and only procedure and had been evaluated in previous single-disease studies. 6,7,14,18,21,26,30,45,46,8 Age was significantly lowest in the uveitis group than in the other groups. 0.042).…”

Section: Introductionmentioning

confidence: 76%

“…Following Robert Machemer, Gholam Peyman, and others, [1][2][3][4][5][6] intravitreal triamcinolone acetonide has increasingly been used in recent studies as treatment for other intraocular proliferative, oedematous, and neovascular diseases, such as diffuse diabetic macular oedema, [7][8][9][10][11][12][13] central retinal vein occlusion, [14][15][16][17] branch retinal vein occlusion, [18][19][20] chronic uveitis, [21][22][23][24][25] persistent pseudophakic cystoid macular oedema, [26][27][28][29] exudative age-related macular degeneration, [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] and other diseases. 6 It has remained unclear so far, whether the various ocular disorders differ in their response to intravitreal triamcinolone acetonide in terms of an increase in visual acuity and a rise in intraocular pressure.…”

Section: Introductionmentioning

confidence: 99%

“…6 It has remained unclear so far, whether the various ocular disorders differ in their response to intravitreal triamcinolone acetonide in terms of an increase in visual acuity and a rise in intraocular pressure. It was, therefore, the purpose of the present review to compare groups of patients with selected ocular diseases with respect to the effect of intravitreal triamcinolone on visual acuity and intraocular pressure.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases

Jonas¹,

Schlichtenbrede²

2007

Eye

View full text Add to dashboard Cite

Purpose Within the last 5 years, intravitreal injections of triamcinolone acetonide have been for a wide variety of ocular diseases with intraocular oedema and neovascularization. With clinical experience accumulating, the question arises for which indication the side effects outweigh the therapeutic efficacy of intravitreal triamcinolone monotherapy. Scope Comparing different diseases, increase in visual acuity was lower in patients receiving intravitreal triamcinolone monotherapy for exudative age-related macular degeneration than in patients with diabetic macular oedema, branch retinal vein occlusion, central retinal vein occlusion, uveitis, and pseudophakic cystoid macular oedema. Rise in intraocular pressure was significantly higher in relatively young patients with uveitis than in any other patient group. Conclusions Improvement in vision after intravitreal triamcinolone monotherapy is highest in non-ischaemic diseases with an intraretinal macular oedema such as pseudophakic cystoid macular oedema; it is lower in partially ischaemic diseases with intraretinal macular oedema such as diabetic macular oedema or retinal vein occlusions; and it is lowest in diseases with a primarily subretinal location of the disease such as exudative age-related macular degeneration. For the latter diseases, intravitreal triamcinolone monotherapy is, therefore, no longer up-to-date, particularly with the upcoming intravitreal application of vascular endothelial growth factor blocking drugs. For diseases with intraretinal oedema, the rule of thumb may be that intravitreal triamcinolone increases vision as much as retinal ischaemia and tissue destruction by the underlying disease allow it. The rise in intraocular pressure is higher in relatively young patients with uveitis than in elderly patients with other reasons for macular oedema.

show abstract

Section: Introductionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases

Jonas¹,

Schlichtenbrede²

2007

Eye

View full text Add to dashboard Cite

show abstract

“…1,2 Treatments include oral or periocular corticosteroids, sometimes given in combination with oral carbonic anhydrase inhibitors, 3 immune-modulating drugs, such as anti-TNF-a therapy [4][5][6] and intravitreally administered triamcinolone (TA). 7,8 Macular oedema in the setting of uveitis, as also for diseases, such as diabetic retinopathy or retinal vein occlusions (RVOs), arises due to a disruption of the blood-retinal barrier, with consecutive exudation and accumulation of serous fluid. 9 Evidence exists that VEGF is not only involved in the pathogenesis of CME in diabetes, RVO, but also in intraocular inflammatory diseases.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

Weiß

Steinbrugger

Weger

et al. 2009

Eye

View full text Add to dashboard Cite

“…Lipocortins inhibit the phospholipase A2 (4,5). In addition to their anti-inflammatory action, corticosteroids exhibit vasoconstrictive (6), and anti-proliferative (7)(8)(9) effects. Corticosteroids can also inhibit angiogenic growth factors and choroidal neovascularization (growth of abnormal new blood vessels from the choroidal vasculature) in several animal studies (10).…”

Section: Introductionmentioning

confidence: 99%

Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

2009

View full text Add to dashboard Cite

Abstract. Recently, the use of triamcinolone acetonide (TA) injection has increased dramatically in treatment for several ocular diseases. Among them, macular diseases such as macular edema due to diabetic retinopathy, venous occlusive diseases, ocular inflammation and age-related macular degeneration (AMD) are very common vision threatening disorders and are great challenges to treat. In these types of chronic retinal diseases, repeated intraocular injections of TA are often required which increases the likelihood of complications. In order to achieve sustained-release, maintain therapeutic levels of TA over longer times and reduce frequency of intravitreal injections, researchers are investigating different implantable devices or injectable systems. However, as of yet, there is no sustained-release product for TA available on the commercial market. This review discusses and compares different sustained-release devices or injectable systems that are currently being developed.

show abstract

Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases

Cited by 155 publications

References 171 publications

Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases

Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

Contact Info

Product

Resources

About